| BÜCHLER, Tomáš, Radim KLAPKA, B. MELICHAR, Petr BRABEC, Ladislav DUŠEK, Rostislav VYZULA a J. ABRAHAMOVA. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Annals of Oncology. OXFORD: OXFORD UNIV PRESS, 2012, roč. 23, č. 2, s. 395-401. ISSN 0923-7534. Dostupné z: https://dx.doi.org/10.1093/annonc/mdr065. |
Další formáty:
BibTeX
LaTeX
RIS
@article{968978,
author = {Büchler, Tomáš and Klapka, Radim and Melichar, B. and Brabec, Petr and Dušek, Ladislav and Vyzula, Rostislav and Abrahamova, J.},
article_location = {OXFORD},
article_number = {2},
doi = {http://dx.doi.org/10.1093/annonc/mdr065},
keywords = {renal cell carcinoma; sorafenib; sunitinib},
language = {eng},
issn = {0923-7534},
journal = {Annals of Oncology},
title = {Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry},
volume = {23},
year = {2012}
}
TY - JOUR
ID - 968978
AU - Büchler, Tomáš - Klapka, Radim - Melichar, B. - Brabec, Petr - Dušek, Ladislav - Vyzula, Rostislav - Abrahamova, J.
PY - 2012
TI - Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry
JF - Annals of Oncology
VL - 23
IS - 2
SP - 395-401
EP - 395-401
PB - OXFORD UNIV PRESS
SN - 09237534
KW - renal cell carcinoma
KW - sorafenib
KW - sunitinib
N2 - Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib-sorafenib or sorafenib-sunitinib sequence. Patients and methods: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib-sorafenib sequence and 122 patients treated with sorafenib-sunitinib sequence. Results: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib-sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib-sorafenib and 84% (95% CI 77% to 91%) for sorafenib-sunitinib patients (P = 0.99). Treatment toxic effects were predictable but a significant proportion of patients (up to 14%-25% for different lines of therapy and used TKI) switched between TKIs or discontinued TKI therapy because of toxicity. Conclusions: In contrast to most of the previously published reports, we have not observed improved PFS or OS for mRCC patients treated with the sorafenib-sunitinib sequence as compared to the sunitinib-sorafenib sequence.
ER -
BÜCHLER, Tomáš, Radim KLAPKA, B. MELICHAR, Petr BRABEC, Ladislav DUŠEK, Rostislav VYZULA a J. ABRAHAMOVA. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. \textit{Annals of Oncology}. OXFORD: OXFORD UNIV PRESS, 2012, roč.~23, č.~2, s.~395-401. ISSN~0923-7534. Dostupné z: https://dx.doi.org/10.1093/annonc/mdr065.
|
